Form 4: HCA Healthcare Executive Granted 8,067 Stock Appreciation Rights

HCA Healthcare's EVP & Chief Legal & Admin Officer, Michael R. McAlevey, was granted 8,067 stock appreciation rights with an exercise price of $482.53.

Summary

• Michael R. McAlevey, Executive Vice President and Chief Legal & Administrative Officer of HCA Healthcare, Inc., was granted 8,067 Stock Appreciation Rights (SARs).
• The SARs have an exercise price of $482.53 per share.
• The grant date for these SARs was January 29, 2026.
• These SARs will vest in four equal annual installments, commencing on January 29, 2027.
• The expiration date for these stock appreciation rights is January 29, 2036.
• Following this transaction, Mr. McAlevey beneficially owns 8,067 derivative securities directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive incentive practices that align management with shareholder interests, without indicating any immediate operational or financial shifts.

Positives

• The grant of Stock Appreciation Rights aligns the executive's incentives with shareholder value creation, as SARs gain value when the company's stock price increases above the exercise price.
• The vesting schedule over four years encourages long-term commitment and performance from a key executive.

Negatives

• No direct negatives are apparent from a standard Form 4 filing, which simply reports a transaction.

Risks

• No specific risks are mentioned within this Form 4 filing, which is a disclosure of an executive compensation event.

Future Outlook

The grant of long-term incentive compensation to a key executive suggests a continued focus on retaining talent and aligning management's interests with the company's long-term performance and shareholder value creation.

Industry Context

Stock Appreciation Rights are a common form of equity-based compensation in the healthcare industry and across various sectors, used to incentivize executives by linking their compensation to the company's stock performance without requiring an upfront investment from the executive. StockSavvy.ai notes this is a standard practice for executive retention and motivation.

Comparison to Industry Standards

• The use of Stock Appreciation Rights (SARs) as a component of executive compensation is a widely accepted practice across industries, including healthcare. Companies like UnitedHealth Group (UNH) and Anthem (ANTM) frequently utilize similar equity-based incentives to align executive interests with long-term shareholder value.
• The vesting schedule of four equal annual installments is typical for long-term incentive grants, comparable to practices at peers such as Tenet Healthcare (THC) or Community Health Systems (CYH), designed to promote executive retention and sustained performance over several years.

Related Party Transactions

• The grant of Stock Appreciation Rights to an executive officer is a related party transaction, common in executive compensation.

Stakeholder Impact

• Shareholders: The grant of SARs aims to align executive incentives with shareholder value creation, potentially benefiting shareholders if the company's stock price appreciates.
• Employees: No direct impact on general employees is indicated by this specific filing.
• Management: The executive receives a long-term incentive award, linking their future compensation to the company's stock performance.

Next Steps

• The SARs will begin to vest in four equal annual installments starting January 29, 2027, allowing the executive to potentially exercise them in the future based on HCA's stock performance.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation grant and does not contain information that would fundamentally alter the investment thesis for HCA Healthcare. It is a standard practice for executive retention and motivation, and while positive for aligning interests, it does not provide new data points for a 'buy' or 'sell' recommendation. Investors should continue to 'hold' based on broader company fundamentals and market conditions.

Keywords

HCA Healthcare, Stock Appreciation Rights, SARs, Executive Compensation, Insider Transaction, Form 4, Michael R. McAlevey, Equity Grant